CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.560
+0.090 (3.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
CytoMed Therapeutics Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Other Revenue | 0.45 | 0.51 | 0.36 | 0.11 | 0.06 | - |
| Revenue | 0.45 | 0.51 | 0.36 | 0.11 | 0.06 | - |
| Revenue Growth (YoY) | -21.95% | 39.52% | 219.67% | 91.43% | - | - |
| Cost of Revenue | -0 | 0 | 0.01 | 0 | 0 | - |
| Gross Profit | 0.45 | 0.5 | 0.36 | 0.11 | 0.05 | - |
| Selling, General & Admin | 0.62 | 0.49 | 0.21 | 0.17 | 0.14 | 0.05 |
| Research & Development | 1.75 | 1.59 | 1.52 | 1.09 | 1.04 | 0.59 |
| Other Operating Expenses | 1.44 | 2.16 | 0.37 | 0.49 | 0.11 | 0.12 |
| Operating Expenses | 3.91 | 4.35 | 2.21 | 1.85 | 1.37 | 0.82 |
| Operating Income | -3.46 | -3.84 | -1.86 | -1.74 | -1.32 | -0.82 |
| Interest Expense | -0.02 | -0.05 | -0.13 | -0.12 | -0.11 | -0.03 |
| Interest & Investment Income | 0.44 | 0.29 | 0 | 0 | - | - |
| Earnings From Equity Investments | 0 | -0.03 | -0.03 | -0.21 | - | - |
| Currency Exchange Gain (Loss) | -0.04 | -0.17 | -0.03 | -0.01 | -0 | -0.01 |
| Other Non Operating Income (Expenses) | -0.07 | -0.22 | - | - | - | - |
| EBT Excluding Unusual Items | -3.15 | -4.03 | -2.04 | -2.08 | -1.42 | -0.85 |
| Gain (Loss) on Sale of Assets | - | - | 0 | - | - | - |
| Other Unusual Items | 0.09 | -0.1 | -1.09 | 0.02 | -0.51 | - |
| Pretax Income | -3.06 | -4.13 | -3.13 | -2.05 | -1.94 | -0.85 |
| Income Tax Expense | 0 | 0 | 0 | - | - | - |
| Earnings From Continuing Operations | -3.06 | -4.13 | -3.13 | -2.05 | -1.94 | -0.85 |
| Minority Interest in Earnings | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -3.06 | -4.13 | -3.13 | -2.05 | -1.94 | -0.85 |
| Net Income to Common | -3.06 | -4.13 | -3.13 | -2.05 | -1.94 | -0.85 |
| Shares Outstanding (Basic) | 12 | 11 | 8 | 7 | 6 | 6 |
| Shares Outstanding (Diluted) | 12 | 11 | 8 | 7 | 6 | 6 |
| Shares Change (YoY) | 29.10% | 34.30% | 14.14% | 17.59% | 6.22% | - |
| EPS (Basic) | -0.27 | -0.39 | -0.40 | -0.30 | -0.33 | -0.15 |
| EPS (Diluted) | -0.27 | -0.39 | -0.40 | -0.30 | -0.33 | -0.15 |
| Free Cash Flow | -3.51 | -3.49 | -1.87 | -2.3 | -1.09 | -1.81 |
| Free Cash Flow Per Share | -0.30 | -0.33 | -0.24 | -0.33 | -0.19 | -0.33 |
| Gross Margin | 100.04% | 99.27% | 97.60% | 96.92% | 92.22% | - |
| Operating Margin | -773.57% | -756.86% | -511.02% | -1528.84% | -2215.85% | - |
| Profit Margin | -684.21% | -813.99% | -860.43% | -1802.21% | -3254.59% | - |
| Free Cash Flow Margin | -783.19% | -687.59% | -514.47% | -2016.27% | -1839.93% | - |
| EBITDA | -3.12 | -3.46 | -1.47 | -1.41 | -1.03 | -0.64 |
| D&A For EBITDA | 0.34 | 0.38 | 0.39 | 0.33 | 0.29 | 0.18 |
| EBIT | -3.46 | -3.84 | -1.86 | -1.74 | -1.32 | -0.82 |
| Advertising Expenses | - | 0.03 | - | 0 | 0.01 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.